Physician profile
Rahul Seth
NPI 1033184692
$9,519.16
in general payments reported to CMS, 2019-2025
19 companies · $2,804 in 2025
The $2,804 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,013 · 2020: $15.32 · 2021: $1,612 · 2022: $2,441 · 2023: $569 · 2024: $64.59 · 2025: $2,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,205 · Food and Beverage: $1,134 · Education: $98.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,205.00 |
| Food and Beverage | $1,134.36 |
| Education | $98.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $2,365.88 | 2025 | Onivyde |
| Celgene Corporation | $2,081.42 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,780.89 | 2022 | |
| Pharmacosmos Therapeutics INC. | $1,626.30 | 2021-2024 | Monoferric |
| Foundation Medicine, INC. | $309.00 | 2022 | |
| Daiichi Sankyo INC. | $197.56 | 2022-2023 | Injectafer |
| Aveo Pharmaceuticals, INC. | $184.45 | 2022-2023 | Fotivda |
| Amgen INC. | $157.90 | 2022-2023 | Vectibix, Lumakras |
| Novocure INC. | $144.56 | 2025 | Optune Gio |
| Adaptive Biotechnologies Corporation | $141.83 | 2023 | Clonoseq |
| Servier Pharmaceuticals LLC | $118.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $113.30 | 2023 | Imfinzi |
| Epizyme, INC. | $112.00 | 2021 | |
| Stryker Corporation | $50.00 | 2025 | Na, Smartlock |
| Merck Sharp & Dohme LLC | $43.51 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $35.00 | 2024 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $30.16 | 2020-2022 | |
| Pfizer INC. | $13.86 | 2023 | |
| Array Biopharma INC | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Seth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.